Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DS-5670a
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
DS-5670a is a monovalent mRNA-based vaccine developed for the prevention of COVID-19. It encodes the receptor-binding domain (RBD) of the spike glycoprotein derived from the original Wuhan strain of SARS-CoV-2. The vaccine utilizes a lipid nanoparticle delivery system to facilitate cellular uptake and expression of the antigen, leading to an immune response characterized by production of neutralizing antibodies against SARS-CoV-2. Developed by Daiichi Sankyo, DS-5670a has demonstrated favorable immunogenicity and safety profiles in clinical trials and has been authorized in Japan for use as a booster immunization against COVID-19[1][2][3][4]. The platform is adaptable for new variants, with bivalent and variant-adapted versions also under development.
- Brand names
- Daichirona
- Other names
- chimeric messenger RNA COVID-19 vaccineDaiichi Sankyo COVID-19 vaccineDaichirona for Intramuscular Injection
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on DS-5670a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DS-5670a.